FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W205980994> ?p ?o ?g. }

• W205980994 endingPage "8" @default.
• W205980994 startingPage "855" @default.
• W205980994 abstract "To study the efficacy of erythropoietinin (EPO) in the treatment of moderate or severe hypoxic-ischemic encephalopathy (HIE) in neonates.Seventy neonates with moderate or severe HIE were randomly assigned to two groups: EPO treatment and control (n=35 each). The EPO treatment group included 22 cases of moderate HIE and 13 cases of severe HIE. The control group included 24 cases of moderate HIE and 11 cases of severe HIE. Thirty-five healthy full-term infants served as normal group. The control group received a conventional treatment. Beside the conventional treatment, the EPO treatment group was intravenously injected with EPO of 200 IU/kg•d, 3 times weekly. Routine blood test was performed every 6 days. EPO dose was adjusted based on the results of the routine blood test. The course of EPO treatment was 2 to 4 weeks. Neonatal Behavioral Neurological Assessment (NBNA) was performed at age of 28 days. The infant development test of Child Development Centre of China (CDCC) was performed at ages of 3 months and 6 months.The percentage of normal NBNA scores in the EPO treatment group was significantly higher than that in the control group at age of 28 days (P<0.05), but was significantly lower than that in the normal group (P<0.01). The CDCC test including physical development index (PDI) and physical development index (MDI) showed the percentage of normal results in the EPO treatment group was significantly higher than in the control group at age of 3 months (P<0.05), but was significantly lower than in the normal group (P<0.01). The CDCC test including PDI and MDI showed that the percentage of normal results in the EPO treatment group was significantly higher than in the control group at age of 6 months. The MDI test results in the EPO treatment group were not significantly different from those in the normal group at age of 6 months, but the percentage of normal results in the PDI test in the EPO treatment group was still significantly lower than that in the normal group (P<0.05).EPO treatment has neuroprotective effects against moderate or severe HIE and improves long-term behavioral neurological developments in neonates." @default.
• W205980994 created "2016-06-24" @default.
• W205980994 creator A5044084703 @default.
• W205980994 creator A5069167008 @default.
• W205980994 creator A5085776979 @default.
• W205980994 creator A5088580824 @default.
• W205980994 creator A5091721802 @default.
• W205980994 date "2011-11-01" @default.
• W205980994 modified "2023-09-23" @default.
• W205980994 title "[Therapeutic effects of erythropoietin on hypoxic-ischemic encephalopathy in neonates]." @default.
• W205980994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22099189" @default.
• W205980994 hasPublicationYear "2011" @default.
• W205980994 type Work @default.
• W205980994 sameAs 205980994 @default.
• W205980994 citedByCount "6" @default.
• W205980994 countsByYear W2059809942013 @default.
• W205980994 countsByYear W2059809942017 @default.
• W205980994 countsByYear W2059809942021 @default.
• W205980994 countsByYear W2059809942022 @default.
• W205980994 countsByYear W2059809942023 @default.
• W205980994 crossrefType "journal-article" @default.
• W205980994 hasAuthorship W205980994A5044084703 @default.
• W205980994 hasAuthorship W205980994A5069167008 @default.
• W205980994 hasAuthorship W205980994A5085776979 @default.
• W205980994 hasAuthorship W205980994A5088580824 @default.
• W205980994 hasAuthorship W205980994A5091721802 @default.
• W205980994 hasConcept C126322002 @default.
• W205980994 hasConcept C187212893 @default.
• W205980994 hasConcept C2778534260 @default.
• W205980994 hasConcept C2778621155 @default.
• W205980994 hasConcept C2909832856 @default.
• W205980994 hasConcept C42219234 @default.
• W205980994 hasConcept C71924100 @default.
• W205980994 hasConceptScore W205980994C126322002 @default.
• W205980994 hasConceptScore W205980994C187212893 @default.
• W205980994 hasConceptScore W205980994C2778534260 @default.
• W205980994 hasConceptScore W205980994C2778621155 @default.
• W205980994 hasConceptScore W205980994C2909832856 @default.
• W205980994 hasConceptScore W205980994C42219234 @default.
• W205980994 hasConceptScore W205980994C71924100 @default.
• W205980994 hasIssue "11" @default.
• W205980994 hasLocation W2059809941 @default.
• W205980994 hasOpenAccess W205980994 @default.
• W205980994 hasPrimaryLocation W2059809941 @default.
• W205980994 hasRelatedWork W1964215069 @default.
• W205980994 hasRelatedWork W205980994 @default.
• W205980994 hasRelatedWork W2150172988 @default.
• W205980994 hasRelatedWork W2375086315 @default.
• W205980994 hasRelatedWork W2765518338 @default.
• W205980994 hasRelatedWork W2946990912 @default.
• W205980994 hasRelatedWork W3029798245 @default.
• W205980994 hasRelatedWork W3031593563 @default.
• W205980994 hasRelatedWork W4220819432 @default.
• W205980994 hasRelatedWork W4283009236 @default.
• W205980994 hasVolume "13" @default.
• W205980994 isParatext "false" @default.
• W205980994 isRetracted "false" @default.
• W205980994 magId "205980994" @default.
• W205980994 workType "article" @default.